Share this story:

Arev Nutrition Sciences Inc. Announces Derek Sider as CFO

Vancouver, British Columbia / TheNewswire / February 8, 2018 - AREV Nutrition Sciences Inc. ("AREV" or the "Company") (CSE - AREV), is pleased to announce Derek Sider has joined the Company as Chief Financial Officer ("CFO"), effective immediately.

Due to the current transaction between the Company and We Grow BC Ltd ("WGBC"), Long Trinh, currently Chief Financial Officer of AREV, has resigned to focus his attention on matters relating to We Grow BC Ltd and closing the transaction with AREV announced on January 17, 2018. The Company is pleased to announce that Derek Sider has been appointed, effective immediately, as Chief Financial Officer ("CFO").

Derek Sider (Derek) is an experienced financial profession with over 17 years in various international business roles.

Most recently Derek spent 6 years in the mining industry in management roles ranging from M&A to corporate administration and corporate tax. He has participated on a variety of international acquisitions, divestitures, joint ventures and other mining deals with values up to $2 billion. His experience includes corporate finance, corporate tax, securities and corporate law matters, public and private debt, deal negotiation, and corporate structuring.

Prior to that, Derek spent 9 years at PricewaterhouseCoopers, in a number of roles including International Tax in Vancouver and Capital Markets in New York, progressing to the senior manager level.

He has served on a number of non-profits boards, most recently as Treasurer/Finance Committee Chair at the Association of Neighborhood Houses, one of BC's largest and oldest charities.

Derek is a designated Chartered Professional Accountant (CGA) with a Masters in Science (Tax) with honors and is currently a candidate for a Masters in Business Law (Osgoode Law).

The Company is also pleased to appoint Denby Greenslade as Corporate Secretary of AREV Nutrition Sciences Inc., effective immediately. Ms. Greenslade has over 15 years of corporate secretarial, corporate governance, and securities regulation experience with a focus on the neutraceutical and mining sector in Canada and Mexico. She has served in several senior management and executive roles for companies listed on the Toronto Stock Exchange, TSX Venture Exchange and Canadian Stock Exchange. During her career, she has been involved in numerous transactions and financings, and has led the evaluation, design, implementation and monitoring of governance programs for several junior mining companies.

Further, the Company has hired a consultant with over 12 years of management experience at TELUS to head a number of important Human Resources initiatives. Amongst other things, the consultant will assist with sourcing and place strategic individuals in key roles moving forward.

The Company, effective immediately, has issued 405,000 stock options to Officers and consultants of the Company at a price of $0.56 for a period of 5 years from the issuance date. 25,000 of these options will vest immediately with the remaining 380,000 options on a 2 year vesting schedule: 1/3 immediately, 1/3 at the 1 year mark and the final 1/3 at the end of the second year.

For further information, contact Stephane Maher, CEO at

On behalf of the Board,

Stephane Maher
Chief Executive Officer & Director

About AREV Nutrition Sciences Inc.
AREV Nutrition Sciences Inc. ("AREV") produces and delivers functional ingredients from its world-class extraction systems. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain Management, Insomnia, Central Nervous System Disorders & Libido. .



Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on